An analysis of the Alzheimer's disease, analyzing a neurodegenerative disease that affects more than half a million Argentines, says a study by scientists from the Conicet and the Leloir Institute Foundation (FIL).
Experimental evidence of patients and animal models suggests that in the affected brain, glucose consumption, the main source of neuronal energy, decreases.
Researchers believe that this variant can be detected in platelets, one of the blood components involved in the coagulation and repair process of the vessel.
"In the platelets, Alzheimer's patients may have brain energy deficiencies and inflammatory and oxidative processes," said Dr. Laura Morelli, research director and FIL's Amyloidosis and Neurodegenerative Laboratory.
Researchers found that in the rats disease, the functional ability of the mitochondrion (cells, in this case, in platelets) produced less energy.
"The isolation of blood vessels we made in the lab was determined and the mitochondrion determined the consumption of oxygen and the ability to generate energy." We compared two groups of animals, a healthy, and a patient, and we saw that the mitochondrion did not work in the final group, "the specialist's details.
According to Morelli, it focuses on the Innovation Program for Research, Diagnosis and Treatment of Alzheimer's Disease Innovation. This has good results "Using plaquetas as an indicator, the brain's energy function".
"This determination will help to reflect on the periphery something that is happening in the middle of the body, and other specific studies have an early diagnosis of Alzheimer's."
When asked about the importance of early detection, Morelli has said that when pathologies confirm in the patient, "brain gymnastics" is beginning to work on cognitive neurorehabilitation programs and that it is necessary to take steps to reduce the levels of cholesterol and blood pressure, physical activity and other health Do some tips.
"Generally, everything works well with good heart, but the reality is that there is no specific treatment or treatment of Alzheimer's to improve the quality of life of the patient." Conicet explains the researcher.
Morelli also stated that it is "essential" to detect risk factors for this type of illness, the evidence of the last 25 years has shown that "the therapy applied to patients in already-installed pathology is ineffective."
"The attention we have to our attention has to be a presymptomatic stage, and we also know that brain changes can be detected before the age of 65, that is, the average age of the disease," said the scientist. .
He added: "This research is still necessary to become a common study, but it is very important to enable biomarkers or indicators to deal with Alzheimer's disease in human beings".